Trial Profile

A study to compare incidence rate of non-vertebral fractures in rheumatoid arthritis patients initiating one of the nine biologic or targeted-synthetic DMARDs: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com